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This ISN-sponsored Forefront in Nephrology meeting, which
has brought together 120 scientists from 21 countries, has
been concerned with various aspects of endothelial function
and dysfunction and their contribution to progression of
chronic kidney disease and/or its cardiovascular
complications. The following themes were discussed in great
depth: (1) phenotypical changes in the vascular endothelium
– permeability, senescence, and apoptosis; (2) regulation of
endothelial nitric oxide (NO) synthase function – caveolar and
shear stress mechanisms, epigenetic regulation,
S-nitrosylation, and Rho-kinase regulation; (3) oxidative stress
and hypoxia-induced changes; (4) organellar dysfunction –
lysosomes, mitochondria, and endoplasmic reticulum; (5)
NO-independent mechanisms of vasomotion – epoxides,
heme oxygenase-1 and carbon monoxide, thromboxane,
tumor necrosis factor-alpha, and uric acid; (6) endothelial
crosstalk with podocytes, monocytes, smooth muscle cells,
and platelets; (7) candidate clinical biomarkers of endothelial
dysfunction – functional testing of macro- and micro-vascular
functions, surrogate markers, circulating detached
endothelial cells, and endothelial precursor cells; and
culminated in Round Table discussion on the diagnosis of
endothelial dysfunction and its treatment options. In
conclusion, this meeting has focused on several key
problems of endothelial cell pathobiology relevant to chronic
kidney disease.
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International Society of Nephrology held a Forefront in
Nephrology meeting on 16–19 March, 2006 in Palisades, NY,
USA. The overarching theme of this Forefronts meeting was
concerned with biology and pathobiology of the endothe-
lium. As this theme is gargantuan, the organizers decided to
artificially constrain the field by presenting the most recent
information and avoiding any overlap with previous Fore-
fronts meetings (Germany, Japan). Yet, two plenary lectures
provided a good ‘aftertaste’ of the major subjects of the
previous meetings – stem cell biology in renal diseases and
impaired angiogenesis as a driving mechanism of inducing
disease.
In the opening lecture, Al Awqati (Columbia University,
NY, USA) summarized recent findings from his laboratory.1,2
Several important messages resounded: (1) there is no single
reliable marker of ‘stemness’ and the need to establish
kidney-specific markers for stem cells; (2) protective micro-
environment of stem cell ‘niche’ and the fitness of renal
papillary microenvironment for this function (in particular,
the presence of a hypoxic milieu that limits oxygen toxicity
and the presence of endothelial cells or endothelial factors
appear to be essential); and (3) repopulation of ischemically
injured renal structures by the mobilized papillary stem cells.
The speaker raised an important question: Does the
pathology of renal medulla and papilla, such as occurs in
sickle cell disease or obstructive uropathy, lead to the
associated loss of this stem cell ‘niche’ and ensuing
progressive chronic kidney disease owing to a defect in stem
cell-induced regeneration. Such a generalization should call
for in-depth study of these conditions and may harbor some
future therapeutic insights.
The second plenary lecture was delivered by Sukhatme
(Harvard Medical School, Beth Israel-Deaconess Center,
Boston, MA, USA), who stressed the need to recognize not
only the ‘bench-to-bedside’ strategy but also the opposite
‘bedside-to-bench’ approach, which eventually culminates in
the return to bedside at a higher level of understanding of
events and better therapeutics. This line of thought was
illustrated with three vignettes: (1) the recently discovered
role of soluble fms-like tyrosine kinase 1 in the pathogenesis
of preeclampsia.3–6 This soluble vascular endothelial growth
factor (VEGF) receptor is increased in preeclampsia and acts
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as a decoy interrupting VEGF and placental growth factor
(PLGF) signaling, thus resulting in glomerular endotheliosis.
(2) Zebrafish as a screening method to discover new genes
that regulate angiogenesis genes. Using a panel of morpho-
lino derivatives of antisense oligodeoxynucleotides, novel
endothelial-specific regulatory heat-shock proteins were
found,7,8 and (3) investigation into the capillary leak
syndrome and attribution of its pathogenesis to the increased
production of angiopoietin-2.9 The roadmap of pathological
events leading to the capillary leak syndrome was outlined as
follows: angiopoietin-2 blockade of Tie-2 signaling, leading
to the activation of Rho kinase and myosin light-chain kinase
phosphorylation, which causes endothelial cell contraction,
gap formation, and disruption of endothelial barrier. This
constructive insight into the pathogenesis of one of the most
dangerous conditions – acute respiratory distress syndrome,
should lead to the expansion of this work and search for
therapeutics capable of disrupting the pathogenetic mechan-
isms or counteracting them.
The theme of Vascular Permeability was expanded by van
Hinsbergh (Free University of Amsterdam, The Netherlands),
who, in addition to providing an overview of tight and
adherence junctions in endothelial layers, has described
studies on the thrombin-induced inactivation of Rho kinase
and myosin light-chain kinase phosphatases leading to the
increased phosphorylation of myosin light-chain and en-
hanced permeability.1–12 This schema is working in tandem
with that proposed by Sukhatme for angiopoietin-2. Vallance
(University College London, UK) presented data on cardi-
ovascular actions of asymmetrical dimethylarginine13–16
followed by some recently discovered actions of NG-NG-
dimethylarginine dimethylaminohydrolase, the enzyme that
metabolizes the endogenous nitric oxide synthase (eNOS)
inhibitor asymmetrical dimethylarginine. The importance of
this enzyme for developmental biology was underscored by
the observation that knockout of the gene is lethal whereas
the heterozygous knockout displayed altered vascular remo-
deling. NG-NG-dimethylarginine dimethylaminohydrolase
was subsequently found to be expressed at the trailing edges
of endothelial cells where it was required for cell permeability
and migration by keeping local cellular asymmetrical
dimethylarginine concentrations low.
The pathogenetic link between endothelial cell senescence
and oxidative stress was developed in a talk by Haendeler (JW
Goethe University, Frankfurt, Germany), who provided an
overview of the involvement of reactive oxygen species,
telomerase reverse transcriptase, mitochondrial dysfunction,
and apoptosis. She discussed the balance between cellular
oxidants and antioxidant systems as the determinants of
cellular aging. Using the cellular disulfide reductase thior-
edoxin-1 (this antioxidant is lost in senescent cells) as an
example, this investigator demonstrated that low-level
oxidative stress increases thioredoxin-1 mRNA and protein
abundance, which then act as a counter-regulatory defense
mechanism and inhibit apoptosis.17,18 Thioredoxin-1, usually
considered as a cytosolic redox regulator, has a polybasic
nuclear import sequence motif and is also present in the
nucleus, where it targets glutathione-S-transferase. Studies
from Rochester, NY, presented by Berk, provided new
information on the thioredoxin-interacting protein (TXNIP)
control of thioredoxin-1 activity, as well as emphasized the
role of glucose-6-phosphate dehydrogenase as the main
source for nicotinamide adenine dinucleotide phosphate
(reduced form), which maintains endothelial redox state.19–22
Some current therapeutic strategies to combat severe
oxidative stress, their disadvantages, and avenues for future
therapeutics were discussed by Wolin (New York Medical
College, Valhalla, NY, USA). This investigator provided a
detailed biochemical overview of cellular sources of reactive
oxygen species, reliable and diverse methods of their
detection, and highlighted the necessity for therapeutic use
of antioxidants to target intracellular signaling pathways.23,24
As an example, apocynin-containing herbs were put forward,
which directly would interfere with electron transport in the
nicotinamide adenine dinucleotide phosphate (reduced
form) oxidases. Also, commonly used drugs such as
angiotensin-converting enzyme inhibitors, angiotensin re-
ceptor blockers and statins could target this enzyme. This
concept was further illustrated by Hintze (New York Medical
College, Valhalla, NY, USA), who showed in in vivo
experiments that inhibition of nicotinamide adenine dinu-
cleotide phosphate (reduced form) oxidase with apocynin
reduces superoxide formation and results in reduced tissue
oxygen consumption. NO competes with oxygen for its
binding site on complex IV of the electron transport chain.
This leads to a decrease in oxygen consumption at any level of
work, measured in the kidney as sodium reabsorption or in
the heart as mechanical work. Despite this, there is no
decrease in ATP production. Therefore, NO is thought to
regulate metabolic efficiency measured as the P/O ratio, that
is, ATP produced divided by oxygen consumed. The
functional significance of this may be a tighter coupling of
the enzymes in the electron transport chain and a reduction
in the amount of superoxide produced. In general, 1–7% of
the total oxygen consumed may form superoxide and the
total amount of superoxide formed increases dramatically as
oxygen consumption increases in proportion to increased
work. In states where NO production/bioactivity is reduced,
such as heart failure or hyperhomocysteinemia, the ability of
NO to modulate tissue oxygen may also be reduced
contributing to the diseased state.25–28
The eNOS enzyme is of critical importance in maintaining
the quiescent endothelial phenotype. Marsden (University of
Toronto, Canada) provided novel insight into the epigenetic
control of this enzyme. In endothelial cells, the enzyme is
present in an active chromatin structure by acetylation of
histones 3 and 4,29,30 whereas in other tissues the enzyme is
silenced and transcriptionally not accessible by repressed
chromatine. The NO released by eNOS mainly exerts its
signaling effects within the endothelium through S-nitrosyla-
tion. Gross (Cornell University, NY, USA) presented emer-
ging knowledge on the mechanisms and importance of
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protein S-nitrosylation (i.e., the addition of nitric oxide (NO)
to sulfur on Cys residues in proteins) for regulating protein
structure/function in health and disease. Notably, virtually all
important functional classes of proteins have been implicated
as physiological and/or pathophysiological S-nitrosylation
targets. He attributed the selective addition of NO to only
certain protein thiols as being determined by the three-
dimensional features in the Cys environment as well as
subcellular access to species that reciprocally mediate
nitrosylation (NO and derivatives) and denitrosylation (low
molecular weight thiols, predominantly glutathione sulfhy-
dryl). Although identification of S-nitrosylation (SNO)
proteins had, in past, been a very laborious undertaking,
tackled one-protein-at-a-time, Gross described a break-
through proteomic technology that now enables unbiased
and high-throughput specification of SNO-Cys residues on
proteins in complex biological mixtures.31 These proteomic
investigations are shedding new light on fundamental
chemical ‘rules’ that determine S-nitrosylation specificity
and are revealing new protein targets that convey the
ubiquitous biological activities of NO.
Another regulatory pathway of the eNOS enzyme was
discussed by Liao (Harvard University, Boston, MA, USA),
who demonstrated that the Rho-kinase enzymes destabilized
the message for eNOS.32–35 Consequently, heterozygous
knockout animals for the Rho-kinase enzyme-1 isoform
displayed increased eNOS expression and reduced intimal
proliferation following carotid ligation. It was suggested that
reduced recruitment of leukocytes into the vessel wall was
contributing to this altered response in the knockout animals.
Interestingly, the eNOS stabilization did not result in blood
pressure, in line with recent data on the pharmacological
Rho-kinase enzyme inhibitor fasudil.
As the kidney functions in a low oxygen environment,
defense mechanisms for hypoxic injury are of great importance
for the preservation of renal function. Eckardt (University
Erlangen, Germany) elaborated on the regulation and role of
the hypoxia-inducible factor-1a and -2a transcription fac-
tors.36–38 Although the former is predominantly present in
tubular epithelium, the latter form appears to be present in
endothelial cells and fibroblasts. The renal hypoxia-inducible
factor response to hypoxia may well merge as an in important
new therapeutic target. Consequently, hypoxia-inducible factor
stabilizers that inhibit prolyl hydroxylase are being explored as
therapeutic tools in this area and can convey nephroprotection
in models such as renal infarction.
The theme of flow-mediated mechanotransduction, re-
levant to the activation of eNOS and vasomotion was the
subject of several talks. Caveolae, considered as one of the
organelles responsible for flow-induced mechanotransduc-
tion, are the site of docking for eNOS. As each endothelial
cell in vivo harbors 5–10 103 caveolae, the highest
concentration of these organelles among all other cell types,
the importance of their function to the endothelium is
difficult to overestimate. Lisanti (Thomas Jefferson Univer-
sity, Philadelphia) presented findings in genetically engi-
neered mice deficient in different caveolins – 1, 2, and 3. The
first two are confined to various cells, including the
endothelium, whereas the caveolin-3 is restricted to skeletal
muscle. The loss of caveolin-1 and consequently the caveolae
by the endothelial cells results in a constitutive activation of
eNOS, and protection from the accelerated atherosclerosis in
apolipoprotein E knockout mice cross-bred with caveolin-1-
deficient animals.39,40 The theme was further explored by
Sessa (Yale University, New Haven, CT, USA), who demon-
strated that the decreased blood flow in a mouse model with
ligation of an external carotid artery, usually resulting in
vasoconstriction, was not observed in caveolin-1 knockout
mice,41–44 but mechanotransduction (expressed as vasocon-
striction) can be rescued by the expression of caveolin-1 only
in endothelial cells of caveolin-1 knockout animals. It appears
that endothelial expression of caveolin-1 is necessary for
short- and long-term control of responses to changes in
blood flow. Berk (University of Rochester, NY, USA)
presented data on flow inhibition of c-Jun-NH2-terminal
kinase (decreased phosphorylation) through inhibition of its
activator – apoptotic signal-regulated kinase-1.20,21 Laminar
flow also prevents tumor necrosis factor-alpha activation of
apoptotic signal-regulated kinase-1. The principal role of
glycocalyx in sensing shear stress and regulation of eNOS
activity was advocated by Stroes (University of Amsterdam,
The Netherlands). The investigator presented data on the role
of hyperlipidemia, hyperglycemia, and inflammation in
affecting glycocalyx thickness, potentially affecting mechan-
osensing, activation of eNOS, and exposing endothelial-
leukocyte adhesion molecules.45,46
Cellular organelles, their dysfunction and endothelial cell
dysfunction (ECD) are topics of emerging importance.
Shayman (University of Michigan, Ann Arbor, USA)
discussed the pathophysiology of lysosomal storage diseases
to illustrate the potential for involvement of these organelles
in vasculopathy. Using a mouse model of Fabry disease, this
investigator has demonstrated that cellular accumulation of
gangliosides is accompanied by the development of ECD.47–49
In the process of exploring the lysosomal compartment, his
team has discovered a novel enzyme – lysosomal phospho-
lipase A2, generated a mouse model deficient in it and
demonstrated that this enzyme is critically involved in the
degradation of surfactant.50,51 Vascular and renal phenotypes
are under the investigation.
Clementi (University of Milan, Italy) reviewed the role of
NO and G-kinase in mitochondrial respiration and biogen-
esis. Although the effects of NO on mitochondrial respiration
are mediated via cytochrome c oxidase52–54 and provide a
minute-to-minute inhibitory regulation of oxygen consump-
tion, chronic effects of NO result in mitochondrial biogen-
esis, potentially increasing mitochondrial respiration and
ATP synthesis. It is possible that the defect of mitochondrial
biogenesis owing to the chronic deficiency in bioavailable NO
may be responsible for the development of obesity.
The balance between protein folding in the endoplasmic
reticulum (ER) and new protein synthesis was the subject of
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the lecture by Ron (New York University). This investigator
provided evidence that imbalance leads to ER stress and that
the kinase the endoplasmic reticulum-resident eukaryotic
initiation factor 2-a kinase (PERK) is responsible for
restoring balance in face of threat of ER stress. This pathway
appear to be coupled to cell death pathway and involves such
downstream targets of PERK signaling as C/EBP homologous
protein (CHOP) and growth arrest and DNA damage-
inducible protein (GADD34).55–57 In mice knockout of
CHOP or GADD34 protects against tunicamycin-induced
acute renal failure (which is due to protein misfolding and
ER stress). The speaker emphasized the potential role of
failure of homeostasis in mediating these effects and
speculated on the therapeutic implications in terms of
manipulating the ER stress response.
The field of cellular organelles harboring the initiators of
disease processes, especially in the area of vascular biology, is
in its infancy, but the available data presented at the meeting
argue that further exploration is necessary.
NO-independent mechanisms controlling vasomotion, as
discussed at the meeting, include epoxides, thromboxane
(TxA2), and carbon monoxide (CO). Within the large family
of epoxyeicosatrienoic acid (EETs), 11,12- and 14,15-EET
have vasodilatory properties. Busse (JW Goethe University,
Frankfurt, Germany) summarized evidence supporting the
role of 11,12-EET as an endothelium-dependent hyperpolar-
izing factor, endothelium-derived hyperpolarizing factor,
exerting its effect by activating potassium channels.58,59 The
theme was echoed by Imig (Medical College of Georgia,
Augasta), who presented data on EET activation of protein
kinase A and reversal of 11,12-EET action by inhibition of
this kinase.60,61 Additional actions of EET’s have recently
emerged. Imig provided evidence that 11,12-EET interferes
with nuclear factor-kappa B signaling, which results in the
inhibition of endothelial–monocyte/macrophage adhesion,
reduces infiltration of the renal parenchyma, and thus exerts
anti-inflammatory activity. This investigator has also noted
that endocannabinoids and their analogs, which also belong
to the epoxide family, have effects on the vasculature similar
to 11,12-EET. Another exciting new feature of EET, described
by Busse, is the participation in angiogenic response.
Through the activation of matrix metalloprotese and cleavage
of heparin-bound epithelial growth factor and activation of
EGF receptor, this endothelium-derived hyperpolarizing
factor is engaged in endothelial proliferation. Moreover,
angiogenic action of VEGF, but not that of basic fibroblast
growth factor may be mediated via activation of EET and can
be abolished by its blockade.58
The actions of exogenous and endogenous CO on the
vasculature were the subject of Nasjletti’s presentation (New
York Medical College, Valhalla, NY, USA). Renal arterial
vessels process heme to CO and biliverdin via a heme
oxygenase (HO)-dependent pathway. This system promotes
renal vasodilation, as interventions that decrease HO
expression/activity promote renal vasoconstriction and
increase the reactivity of the renal vasculature to constrictor
stimuli.62–64 The vasodilator function ascribed to the heme-
HO system relies on CO and biliverdin acting in a
coordinated manner, with biliverdin serving along with its
reduced derivative bilirubin as antioxidants. In this regard,
CO mediates vasoconstriction or vasodilation depending on
the status of pathways, which generate or dispose of reactive
oxygen and/or nitrogen species. CO-induced constriction of
renal arterial vessels is linked to the promotion of oxidative
stress via mechanisms that involve NOS uncoupling, along
with the activation of vascular nicotinamide adenine
dinucleotide phosphate (reduced form) and xanthine oxi-
dases. CO-induced dilation of renal arterial vessels is
attributable to the stimulation of calcium-activated potas-
sium channels in vascular smooth muscle. Importantly,
biliverdin and bilirubin negate the pro-oxidant action of CO
and thus enable the gas to effect vasodilation. These findings
indicate that the renal vasoregulatory function of HO-
derived CO is critically dependent on the antioxidant
effectiveness of HO-derived biliverdin/bilirubin to offset the
pro-oxidant actions of CO.
Thromboxane A2 and its receptor (TxA2/TxR), constitut-
ing a powerful vasoconstrictor pathway, were in focus of
Wilcox’s talk (Georgetown University, Washington, DC,
USA). From the initial observation that Tx blockers prevent
development of hypertension in two kidney/one clip
model,65,66 the investigator showed that cycloxygenase-2 is
the predominant enzyme for TxA4 generation and that
angiotensin-2 infusion does not result in the development of
hypertension in TxR-deficient mice. The cascade of events
leading to ECD, as unleashed by TxA2, includes the
suppression of NO synthesis and stimulation of superoxide
generation.
The role of uric acid in the development of endothelial cell
activation was discussed by Johnson (University of Florida,
Gainesville, FL, USA). His team has generated a wealth of
data in support of this controversial notion.67–70 Nowadays
fructose intake may be directly related to an increased uric
acid production as humans have lost during evolution the
uric acid-catabolizing enzyme uricase. Data were presented
such that increase in uric acid can reduce NO availability,
stimulate vascular smooth muscle cell proliferation, and
result in pre-glomerular lesions that have been associated
with development of hypertension.
Another new concept of endothelial dysfunction was
presented by Stehouwer (University of Maastricht, The
Netherlands), who reviewed the subject of insulin resistance
and illustrated the presence of perivascular fat in obesity.71–73
It was shown that inflammatory fat-derived cytokines such as
tumor necrosis factor-alpha may interfere with endothelium-
dependent vasodilation. As an example, the effects of insulin
on NO activity were impaired by tumor necrosis factor-alpha
thus disbalancing the stimulatory effects of insulin on
endothelin release.
The theme of endothelial crosstalk with other cells, like
platelets, smooth muscle cells, podocytes, and leukocytes, has
been devoted a special session. Radomski (Trinity College,
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Dublin) reviewed endothelial–platelet interactions and pre-
sented new data obtained with the nanosensors of NO and
peroxynitrite. The well-known action of NO preventing
platelet aggregation is opposed by peroxynitrite. The latter
product of the reaction of NO with superoxide ion is
responsible for the activation of matrix metalloproteinase-2,
which promotes platelet aggregation.74,75 Acting together
with other platelet factors such as VEGF and fibroblast
growth factor, this will also facilitate angiogenesis. Through
these mechanisms, platelets have been involved in cancer
metastasis as well.
After reviewing the modes of endothelial–smooth muscle
cell interaction, Sandow (University of New South Wales,
Australia) turned the focus to myoendothelial gap junctions
(MEGJ). These products of interaction between hemichan-
nels expressed on the opposing surfaces of endothelial and
smooth muscle cells have been shown to offer selectivity in
transferring signaling molecules, like cyclic adenosine mono-
phosphate and cyclic guanosine monophosphate,76 depend-
ing on the connexin make-up of the channels. They also
provide the pathway for targeting of endothelium-derived
hyperpolarizing factor, synthesized by the endothelium, to
the adjacent smooth muscle cell. As MEGJ have to cross
internal elastic lamina, the speaker provided strong morpho-
logic evidence of the existing holes in this membrane
separating endothelial and smooth muscle cells. There is
evidence that under pathophysiologic conditions, MEGJ
communication of endothelium-derived hyperpolarizing
factor is impaired, thus perturbing the execution of
vasodilation. The MEGJ probably are of most importance
in resistance vessels where they display a remarkable
heterogeneity with regard to activity. For example, femoral
arteries and primary mesenteric arteries have negligible
MEGJ expression, whereas tertiary mesenteric branches have
abundant expression. In spontaneously hypertensive rats the
activity of MEGJ is downregulated.
Godson (University of Dublin, Ireland) focused on
various actions of lipoxin 4 (LxA4). Produced by leukocytes
and monocytes, as well as platelets, LxA4 anti-inflammatory
action is mediated via inhibition of chemotaxis, leukocy-
te–endothelial cell adhesion and transmigration, and stimula-
tion of phagocytosis of apoptotic polymorphonuclears and
monocytes.77,78 Using a sophisticated proteomic screen of
macrophages subjected to LxA4, it was found that it exerts
dephosphorylation of myosin IIA, which may explain
stimulation of phagocytosis. In addition, evidence was
presented that LxA4 interferes with phosphorylation of
VEGF receptor-2, thus potentially modulating angiogenesis.
LxA4 interferes with platelet-derived growth factor and
transforming growth factor-b signaling, thus potentially
modulating epithelial–mesenchymal transformation and con-
tributing to its antifibrotic action in chronic kidney disease.
Interactions of endothelial cells and podocytes were
masterfully dissected by Quaggin (University of Toronto,
Canada). This investigator, making use of genetically
engineered mice overexpressing or deficient in VEGF-164
synthesis exclusively in podocytes, examined structure–func-
tional consequences of these homeostatic glomerular pertur-
bations.79 The phenotype of mice deficient in podocyte
synthesis of VEGF is that of glomerular fibrin deposition,
endotheliosis, and proteinuria, despite normal podocyte
morphology. On the other hand, when podocytes over-
expressed VEGF, as a result of deletion of Von Hippel-Lindau
protein rendering the cell to exhibit a hypoxic phenotype,
mice develop crescentic glomerulonephritis with the pro-
liferation of podocytes. These studies establish a novel
paradigm for pathogenesis of vasculitis – pathology of
podocytes, – to complement the existing immunologic
pathways.
The theme on Pathogenetic Candidate Markers of ECD
was the subject of several presentations. Zoccali (University
of Calabria, Italy) reviewed data on the predictive value of
asymmetrical dimethylarginine in forecasting cardiovascular
complications in general population and in chronic kidney
disease.80,81 This investigator has also reviewed the existing
candidate markers of endothelial dysfunction, advantages
and disadvantages of their use.
Rabelink (Leiden University, The Netherlands) went into
detail with respect to potential endothelial repair re-
sponses.82–84 Particularly, under conditions of prolonged
redox signaling endothelial integrity becomes dependent
upon re-endothelialization of circulating precursor cells.
Using lineage tracking in mouse models, it was shown that
these re-endothelializing cells derive from a common myeloid
precursor and that risk factors such as diabetes may alter the
immunogenic properties of these myeloid-derived endothe-
lial cells unfavorably. The subject of vascular injury was
further explored by Haller (Hannover Medical School,
Germany), who presented his team’s findings on the stress-
induced detachment of vascular endothelial cells and their
appearance in the circulation – circulating endothelial cells.
These cells may serve as a marker of ongoing vascular
damage, as they are abundant in patients with vasculitis.85,86
circulating endothelial cells express leukocyte adhesion
molecules, which facilitate their co-adherence to activated
leukocytes, the mechanism that may participate in the
generation of systemic pro-inflammatory changes.
The detection of ECD in humans involves testing of flow-
mediated vasodilation, reactive and thermal hyperemic
responses using laser Doppler flowmetry, complex analysis
of aortic pulse wave propagation, and other modalities, as
reviewed by Deanfield (University College London), Stewart
(New York Medical College, Valhalla, NY, USA), and London
(Hospital Manhes, Paris). Neither of these techniques, used
separately, is a strong indicator of ECD and predictor of
cardiovascular disease.87–89 In fact, London demonstrated
convincing data that pulse wave analysis cannot be reliably
used for the assessment of endothelial function. Interestingly,
Deanfield demonstrated that flow-mediated dilation has a
perfect Gaussian distribution in young subjects, suggesting
that this phenomenon represents a normal biological
variable. This means that endothelial dysfunction probably
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represents a shift in the distribution with all the associated
problems in risk detection rate and false-positive values. The
theme that was common to all these lectures and the
following Round Table discussion contained the requirement
for the preclinical diagnosis of ECD.
This subject of (pre)clinical diagnosis of ECD and impend-
ing cardiovascular complications was further explored at a
Round Table discussion chaired by Ritz (University of
Heidelberg, Germany) with most active participation of the
audience. Again, the motif of early preclinical diagnosis has
resounded, as well as the sentiment that neither of currently
used methodologies for diagnosis is satisfactory. It was argued
that it is necessary to define an optimal and practicable set of
markers that test diversified functions of the endothelium –
vasomotion, angiogenesis, coagulation, fibrinolysis, anti-inflam-
matory – to enable the construction of an algorithm with the
maximal receiver-operated characteristic area under the curve.
In view of the limited abilities of individual centers to conduct
such a study, the difficulty of the task at hand implied the need
for international cooperation and consortia in providing
distinct sites for testing selected parameters for other centers.
All in all, much dissatisfaction was expressed with the current
definition of ECD and the robustness of diagnostic procedures.
Three days of the conference promoted multiple dialogs
between the participants practicing bench or bedside work or
both, turning this secluded site on the banks of the Hudson
into a trading point between the basic and clinical research. It
is this international comradery that bridges gaps between
disciplines and disseminates ideas, turning them into seeds
for future discoveries.
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